TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06583499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainable nutrition education based on the transtheoretical model
Description: Before the intervention begins, the Sustainable Nutrition Behaviour Change Stage Survey will be administered to determine participants' training stage. In addition, the Transtheoretical Model (TTM) Based Sustainable Nutrition Scales will be administered to evaluate the effectiveness of the training programme.~TTM Based Nutrition Training Programme consists of 11 modules developed according to the stages of the model.The methodology and tools used are aligned with the objectives of the training programme.The training modules are offered twice a week, with each session lasting a maximum of 40 minutes and continues for a total of 5 weeks. Participants may attend more than one training session in order to develop behaviours that increase adherence to a sustainable diet. At the end of the training programme, data from the Transtheoretical Model-Based Sustainable Nutrition Behaviour Scale will be collected again and evaluated by comparison with the baseline data set..
Study: NCT06216210

Intervention type: DRUG
Intervention: opioid-FREE anesthesia.
Description: They received opioid-free anesthesia. These patients were provided a multimodal combination infusion. The administration of this infusion commenced at a dosage of 0.2 micrograms per kilogram per hour of dexmedetomidine. The Modified Mulimix cocktail, consisting of dexmedetomidine at a concentration of 10 ug/ml, Ketamine at a concentration of 2.5 mg/ml, and Lignocaine at a concentration of 20 mg/ml, was administered to a patient weighing 100 kg and if the weight is 110 Kg the rate will be increased by 10 percent, etc.,

Intervention type: DRUG
Intervention: opioid-CONTAINING anesthesia.
Description: The process of inducing anesthesia included the injection of fentanyl at a dosage of 2 micrograms per kilogram during the induction phase. Additionally, morphine was administered at a dose of 0.03 milligrams per kilogram at the time of port insertion.
Study: NCT06169267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration/biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration/biopsy
Study: NCT05917171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: painTRAINER
Description: painTRAINER is an 8 week online behavioral pain coping skills training program derived from cognitive behavioral therapy approaches, which includes 45 minute behavioral coping sessions to be completed over 8 weeks. Weekly sessions are guided by an automated coach that teaches skills for coping with pain.
Study: NCT06579690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.4% sodium bicarbonate solution
Description: Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.4% sodium bicarbonate solution
Description: Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.4% sodium bicarbonate solution
Description: Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: The comparision group will receive 50 mls of 0.9% Normal Saline
Study: NCT06169267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration/biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration/biopsy
Study: NCT06579846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline and exercise
Description: Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change.~Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25.~Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytisinicline
Description: Same intervention as the experimental group without directed exercise prescription
Study: NCT06169267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Listen to music

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05689047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 330 mg
Description: Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 500 mg
Description: Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 660 mg
Description: Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine 360 mg
Description: Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine 360 mg
Description: Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine 540 mg
Description: Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
Study: NCT05114213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC chemotherapy
Description: The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC chemotherapy
Description: The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
Study: NCT05689047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine 720 mg
Description: Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate (Pyramax) 360 mg/120 mg
Description: Participants with weight \>=24 to \<45 kg will receive dose of 360/120 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine- artesunate (Pyramax) 540 mg/180 mg
Description: Participants with weight \>=45 to \<65 kg will receive 540/180 mg dose of Pyronaridine-artesunate (Pyramax) tablets under fasting condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate (Pyramax) 720 mg/240 mg
Description: Participants with weight \>=65 kg will receive 720/240 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.
Study: NCT05362747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss and produce vouchers
Description: Participants will receive weekly 30-minute, individual, in-person lifestyle counseling delivered by trained interventionists (e.g., registered dietitians) that consists of behavioral, dietary, and physical activity counseling. ProduceRx vouchers will be in the form of Food Bucks and will be provided at each session.
Study: NCT05324540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool therapy
Description: Application of cool therapy. A chilled (between 5C and 10C) instrument will be applied to the oblique sinus while the patient is in atrial fibrillation.
Study: NCT05129488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All participants received Biotrue ONEday lenses with and without an alternate packaging solution (EPG03)
Description: Participants were given both Commercially available Biotrue ONEday lenses and Biotrue ONEday Contact Lenses with EPG03 Packaging Solution. Lens material is made from a hydrophilic copolymer of 2- hydroxyethyl methacrylate and N-vinylpyrrolidone and is 78% water by weight when immersed in saline solution.EPG03 Packaging Solution contains a phosphate buffered saline solution containing potassium chloride, poloxamine, poloxamer 181, glycerol (glycerin), erythritol, and polyquaternium-1.
Study: NCT06241495

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oil will be applied to the individuals included in the study. During the semen sample giving process, coconut oil (placebo) will be applied with a diffuser.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aromatherapy will be applied to the individuals included in the study. During the semen sample giving process, lavender oil will be applied with a diffuser.
Study: NCT04455958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT05301088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate Scent
Description: Chocolate Scent:Children in this group will be given chocolate scent sniffing as a non-pharmacological distraction method.~Stress Ball:Stress ball squeezing will be used as a non-pharmacological distraction method for children in this group.
Study: NCT04455958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06055855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Two-Needle Arthrocentesis
Description: Participants in this group will undergo arthrocentesis using the traditional two-needle technique. The procedure involves the placement of one or two needles into the temporomandibular joint (TMJ) to irrigate the joint space. Needle placement is guided by anatomical landmarks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery-Guided Arthrocentesis
Description: Participants in this group will receive arthrocentesis facilitated by a surgical guide. The guide is generated through pre-operative planning and is designed to aid in the accurate placement of the needle into the TMJ.
Study: NCT05375552

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will experience two repeated 20 minute sessions of tDCS (1.2 mA), with a 10-minute break.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will experience two repeated 20 minute sessions of tDCS (1.2 mA), with a 10-minute break.
Study: NCT06462651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri
Description: Supplementation with drops containing L. reuteri once daily for 21 consecutive days
Study: NCT04927234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko™ therapy
Description: Neuro-muscular electrical stimulation of the peroneal nerve
Study: NCT05743010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1401
Description: APL-1401 capsules orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules orally once daily
Study: NCT04730583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kybella
Description: Injection into the cutaneous Neurofibromas lesion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064nm laser
Description: Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 755nm Alexandrite Laser
Description: Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
Study: NCT06462651

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation with identical drops without L. reuteri once daily for 21 consecutive days
Study: NCT05739851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 2.5/500mg (Before)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 2.5/500mg (Before)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 2.5/500mg (After)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 2.5/500mg (After)
Description: single dose administration (one tablet once a day)
Study: NCT06386614

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine treatment
Description: Both groups were given routine treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: Both groups were given routine treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The common group routine training used sham TDCS stimulation, and the experimental group used real TDCS stimulation
Study: NCT05563753

Intervention type: DRUG
Intervention: ABT
Description: any antibiotic therapy in the first week of life
Study: NCT06020560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin Prefilled Syringe
Description: Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin profiled syringe
Description: Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
Study: NCT05413252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practice Facilitation
Description: Practices will be assigned a practice facilitator who will support practices in implementing all practice redesign components associated with TBC for HTN management.
Study: NCT06126757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PelviSense-assisted pelvic floor muscle training
Description: The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays the electrical activity of the PFMs on the user's mobile device. The re-usable sensor can be attached to the user's perineal region, and when positioned correctly, the width of the sensor is oriented along the medial-lateral axis, and the length is oriented along the anterior-posterior axis of the perineal region. The sensor detects PFM activity as the voltage between the two surface electrodes and transmits this activity to the data acquisition unit, which processes the signal and conveys it to a smartphone via a Wi-Fi connection. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Pelvic Floor Muscle Training Exercise will be performed without the assistance of the PelviSense Device.
Study: NCT06544811

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Program
Description: A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cultural Smoking Cessation Program
Description: A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking and has been developed for American Indian and Alaska Native persons.
Study: NCT04974294

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: random allocation 1:1:1 IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: random allocation 1:1:1 IM injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline for injection
Description: random allocation 1:1:1 IM injection
Study: NCT06304142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
Study: NCT05864105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PM8002
Description: PM8002 20mg/kg Q2W
Study: NCT06312878

Intervention type: OTHER
Intervention: Describe the anatomy of the IVC in the case of an anatomical variant
Description: Evaluated technique by collecting data from the medical record.
Study: NCT06582134

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham BMBI
Description: Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g., 1-2-3 and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
Study: NCT06197594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation techniques
Description: Proprioceptive neuromuscular facilitation techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rebound Therapy
Description: Rebound Therapy
Study: NCT05150535

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionation Radiotherapy.
Description: Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionation radiotherapy
Description: Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.
Study: NCT05864105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
Study: NCT06054113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Administered via CIVI
Study: NCT05509166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-affirmative Cognitive Behavioral Therapy
Description: 10-session LGBTQ-affirmative psychotherapy using CBT techniques

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LGBTQ-affirmative Treatment-As-Usual
Description: 10-session LGBTQ-affirmative psychotherapy